12,214 real negative results, null findings, and replication failures in Medicine. Search the index →
WASTE indexes published research — it does not host or republish full papers. Each entry is a metadata record compiled from open scholarly databases; the abstract is shown in full only where the paper is openly licensed, otherwise a short excerpt under fair use. Classifications are automated and approximate.
Olvert A. Berkhemer, Puck Fransen, Debbie Beumer et al. · 2014 · New England Journal of Medicine
BACKGROUND: In patients with acute ischemic stroke caused by a proximal intracranial arterial occlusion, intraarterial treatment is highly effective for emergency revascularization. However, proof of a beneficial effect on functional…
View details →Els van Nood, Anne Vrieze, Max Nieuwdorp et al. · 2013 · New England Journal of Medicine
BACKGROUND: Recurrent Clostridium difficile infection is difficult to treat, and failure rates for antibiotic therapy are high. We studied the effect of duodenal infusion of donor feces in patients with recurrent C. difficile infection.…
View details →Thomas G. Brott, Robert W. Hobson, George Howard et al. · 2010 · New England Journal of Medicine
BACKGROUND: Carotid-artery stenting and carotid endarterectomy are both options for treating carotid-artery stenosis, an important cause of stroke. METHODS: We randomly assigned patients with symptomatic or asymptomatic carotid stenosis to…
View details →The ACCORD Study Group · 2010 · New England Journal of Medicine
BACKGROUND: We investigated whether combination therapy with a statin plus a fibrate, as compared with statin monotherapy, would reduce the risk of cardiovascular disease in patients with type 2 diabetes mellitus who were at high risk for…
View details →Mark R. Gilbert, James J. Dignam, Terri S. Armstrong et al. · 2014 · New England Journal of Medicine
BACKGROUND: Concurrent treatment with temozolomide and radiotherapy followed by maintenance temozolomide is the standard of care for patients with newly diagnosed glioblastoma. Bevacizumab, a humanized monoclonal antibody against vascular…
View details →Bertram Pitt, Marc A. Pfeffer, Susan F. Assmann et al. · 2014 · New England Journal of Medicine
BACKGROUND: Mineralocorticoid-receptor antagonists improve the prognosis for patients with heart failure and a reduced left ventricular ejection fraction. We evaluated the effects of spironolactone in patients with heart failure and a…
View details →Freddie C. Hamdy, Jenny Donovan, J. Athene Lane et al. · 2016 · New England Journal of Medicine
BACKGROUND: The comparative effectiveness of treatments for prostate cancer that is detected by prostate-specific antigen (PSA) testing remains uncertain. METHODS: We compared active monitoring, radical prostatectomy, and external-beam…
View details →John B. Holcomb, Barbara C. Tilley, Sarah Baraniuk et al. · 2015 · JAMA
IMPORTANCE: Severely injured patients experiencing hemorrhagic shock often require massive transfusion. Earlier transfusion with higher blood product ratios (plasma, platelets, and red blood cells), defined as damage control resuscitation,…
View details →Gregory G. Schwartz, Anders Olsson, Markus Abt et al. · 2012 · New England Journal of Medicine
BACKGROUND: In observational analyses, higher levels of high-density lipoprotein (HDL) cholesterol have been associated with a lower risk of coronary heart disease events. However, whether raising HDL cholesterol levels therapeutically…
View details →Joseph P. Broderick, Yuko Y. Palesch, Andrew M. Demchuk et al. · 2013 · New England Journal of Medicine
BACKGROUND: Endovascular therapy is increasingly used after the administration of intravenous tissue plasminogen activator (t-PA) for patients with moderate-to-severe acute ischemic stroke, but whether a combined approach is more effective…
View details →G. Michael Felker, Kerry L. Lee, David A. Bull et al. · 2011 · New England Journal of Medicine
BACKGROUND: Loop diuretics are an essential component of therapy for patients with acute decompensated heart failure, but there are few prospective data to guide their use. METHODS: In a prospective, double-blind, randomized trial, we…
View details →John Myburgh, Simon Finfer, Rinaldo Bellomo et al. · 2012 · New England Journal of Medicine
BACKGROUND: The safety and efficacy of hydroxyethyl starch (HES) for fluid resuscitation have not been fully evaluated, and adverse effects of HES on survival and renal function have been reported. METHODS: We randomly assigned 7000…
View details →The HPS2-THRIVE Collaborative Group · 2014 · New England Journal of Medicine
BACKGROUND: Patients with evidence of vascular disease are at increased risk for subsequent vascular events despite effective use of statins to lower the low-density lipoprotein (LDL) cholesterol level. Niacin lowers the LDL cholesterol…
View details →Brad H. Rovin, Richard Furie, Kevin Latinis et al. · 2012 · Arthritis & Rheumatism
OBJECTIVE: To evaluate the efficacy and safety of rituximab in a randomized, double-blind, placebo-controlled phase III trial in patients with lupus nephritis treated concomitantly with mycophenolate mofetil (MMF) and corticosteroids.…
View details →Eric F. Morand, Richard Furie, Yoshiya Tanaka et al. · 2019 · New England Journal of Medicine
BACKGROUND: Anifrolumab, a human monoclonal antibody to type I interferon receptor subunit 1 investigated for the treatment of systemic lupus erythematosus (SLE), did not have a significant effect on the primary end point in a previous…
View details →Samantha Budd Haeberlein, Paul Aisen, Frederik Barkhof et al. · 2022 · The Journal of Prevention of Alzheimer s Disease
BACKGROUND: Alzheimer's disease is a progressive, irreversible, and fatal disease for which accumulation of amyloid beta is thought to play a key role in pathogenesis. Aducanumab is a human monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta. OBJECTIVES: We evaluated the efficacy and safety of aducanumab in early Alzheimer's disease. DESIGN: EMERGE and ENGAGE were two randomized, double-blind, placebo-controlled, global, phase 3 studies of aducanumab in patients with early Alzheimer's disease. SETTING: These studies involved 348 sites in 20 countries. PA
View details →Christoph D. Spinner, Robert Gottlieb, Gerard J. Criner et al. · 2020 · JAMA
Importance: Remdesivir demonstrated clinical benefit in a placebo-controlled trial in patients with severe coronavirus disease 2019 (COVID-19), but its effect in patients with moderate disease is unknown. Objective: To determine the…
View details →Dominik Pfister, Nicolás Gonzalo Núñez, Roser Pinyol et al. · 2021 · Nature
Abstract Hepatocellular carcinoma (HCC) can have viral or non-viral causes 1–5 . Non-alcoholic steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has been approved for treating HCC, but biomarker-based stratification of patients for optimal response to therapy is an unmet need 6,7 . Here we report the progressive accumulation of exhausted, unconventionally activated CD8 + PD1 + T cells in NASH-affected livers. In preclinical models of NASH-induced HCC, therapeutic immunotherapy targeted at programmed death-1 (PD1) expanded activated CD8 + PD1 + T cells within tumours but did n
View details →Marie Bakitas, Tor D. Tosteson, Zhigang Li et al. · 2015 · Journal of Clinical Oncology
PURPOSE: Randomized controlled trials have supported integrated oncology and palliative care (PC); however, optimal timing has not been evaluated. We investigated the effect of early versus delayed PC on quality of life (QOL), symptom…
View details →Pierre Asfar, Ferhat Meziani, Jean‐François Hamel et al. · 2014 · New England Journal of Medicine
BACKGROUND: The Surviving Sepsis Campaign recommends targeting a mean arterial pressure of at least 65 mm Hg during initial resuscitation of patients with septic shock. However, whether this blood-pressure target is more or less effective…
View details →Domenica A. Delgado, Bradley S. Lambert, Nickolas Boutris et al. · 2018 · JAAOS Global Research and Reviews
Background: The visual analog scale (VAS) is a validated, subjective measure for acute and chronic pain. Scores are recorded by making a handwritten mark on a 10-cm line that represents a continuum between “no pain” and “worst pain.”…
View details →G. L. Andriole, E. David Crawford, Robert L. Grubb et al. · 2012 · JNCI Journal of the National Cancer Institute
BACKGROUND: The prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial was undertaken to determine whether there is a reduction in prostate cancer mortality from screening using serum…
View details →Martín Cowie, Holger Woehrle, Karl Wegscheider et al. · 2015 · New England Journal of Medicine
BACKGROUND: Central sleep apnea is associated with poor prognosis and death in patients with heart failure. Adaptive servo-ventilation is a therapy that uses a noninvasive ventilator to treat central sleep apnea by delivering…
View details →Mark R. Gilbert, Meihua Wang, Kenneth Aldape et al. · 2013 · Journal of Clinical Oncology
PURPOSE: Radiotherapy with concomitant and adjuvant temozolomide is the standard of care for newly diagnosed glioblastoma (GBM). O(6)-methylguanine-DNA methyltransferase (MGMT) methylation status may be an important determinant of…
View details →Nicholas J. Robert, Véronique Dièras, John A. Glaspy et al. · 2011 · Journal of Clinical Oncology
PURPOSE: This phase III study compared the efficacy and safety of bevacizumab (BV) when combined with several standard chemotherapy regimens versus those regimens alone for first-line treatment of patients with human epidermal growth…
View details →Lawrence S. Honig, Bruno Vellas, Mark Woodward et al. · 2018 · New England Journal of Medicine
BACKGROUND: Alzheimer's disease is characterized by amyloid-beta (Aβ) plaques and neurofibrillary tangles. The humanized monoclonal antibody solanezumab was designed to increase the clearance from the brain of soluble Aβ, peptides that may…
View details →Carlos A. Morillo, José Antônio Marin‐Neto, Álvaro Avezum et al. · 2015 · New England Journal of Medicine
BACKGROUND: The role of trypanocidal therapy in patients with established Chagas' cardiomyopathy is unproven. METHODS: We conducted a prospective, multicenter, randomized study involving 2854 patients with Chagas' cardiomyopathy who…
View details →Vivek Y. Reddy, Shephal K. Doshi, Saibal Kar et al. · 2017 · Journal of the American College of Cardiology
BACKGROUND: The PROTECT AF (WATCHMAN Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) trial demonstrated that left atrial appendage closure (LAAC) with the Watchman device (Boston Scientific, St.…
View details →Ventura Simonovich, Leandro Daniel Burgos Pratx, Paula Scibona et al. · 2020 · New England Journal of Medicine
BACKGROUND: Convalescent plasma is frequently administered to patients with Covid-19 and has been reported, largely on the basis of observational data, to improve clinical outcomes. Minimal data are available from adequately powered…
View details →Robert Gottlieb, Ajay Nirula, Peter Chen et al. · 2021 · JAMA
Importance: Coronavirus disease 2019 (COVID-19) continues to spread rapidly worldwide. Neutralizing antibodies are a potential treatment for COVID-19. Objective: To determine the effect of bamlanivimab monotherapy and combination therapy…
View details →